Information  X 
Enter a valid email address

Tiziana Life Sci PLC (TILS)

  Print      Mail a friend

Friday 27 April, 2018

Tiziana Life Sci PLC

Issue of Equity

RNS Number : 3188M
Tiziana Life Sciences PLC
27 April 2018
 

Tiziana Life Sciences plc

("Tiziana" or the "Company")

Issue of equity

27 April 2018 

Tiziana Life Sciences plc (AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, today announces that it has allotted 23,014 ordinary shares in the Company at a price of 70p per share. This issue is in relation to a shortfall in capitalized interest due to a former holder of the Company's Class C Convertible Loan Notes which was discovered during the annual audit process.

Application will be made to the London Stock Exchange plc to admit the 23,014 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 3 May 2018. The new ordinary shares will rank pari passu with the existing ordinary shares.

Following the issue of shares detailed above the so enlarged issued share capital of the Company will comprise 126,927,299 ordinary shares of 3p each.

 Contacts

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

 

+44 (0)20 7493 2853

Cairn Financial Advisers LLP (Nominated adviser)

Liam Murray / Jo Turner

 

+44 (0)20 7213 0880

 About Tiziana Life Sciences

Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered human anti-CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 For more information go to http://www.tizianalifesciences.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEFQLLLVZFFBBZ

a d v e r t i s e m e n t